Citizens reiterates Abivax stock rating with $114 price target

Citizens has reiterated its Market Outperform rating and $114 price target for Abivax (NASDAQ:ABVX) following new detailed results from Phase 3 trials that reinforced the compelling safety profile of its obefazimod treatment for ulcerative colitis. This positive data, consistent with prior top-line findings, underpins the stock's 758% return over the past year and its current near 52-week high. Analysts are now focused on upcoming data regarding obefazimod's efficacy in treatment-resistant patients, a potential key differentiator, with JMP Securities and Guggenheim also maintaining positive ratings and price targets.

Analysis

Bitcoin price today: dips after record high above $125k; ETF inflows drive gains Investing.com - Citizens has reiterated its Market Outperform rating and $114 price target on Abivax (NASDAQ:ABVX), citing positive safety data for the company’s obefazimod treatment. The stock, currently trading at $83.92, has delivered an impressive 758% return over the past year and sits near its 52-week high of $92.91. The research firm highlighted new detailed results from the first of two late-breaking abstracts presented at the United European Gastroenterology (UEG) meeting in Berlin, which reinforced the "compelling and differentiated safety/tolerability profile" of obefazimod. The presented data included adverse events from the pooled Phase 3 ABTECT-1 and ABTECT-2 trials, specifically those occurring in more than 1% of patients receiving the drug, which Citizens noted was consistent with the top-line results released in July. Citizens is awaiting results from the second late-breaking abstract, which is expected to provide information on obefazimod’s effectiveness in patients who have previously failed treatment with one to four advanced therapies. The firm maintains its $114 risk-adjusted, discounted cash flow-derived price target on Abivax, viewing the potential efficacy in treatment-resistant patients as "another key differentiating attribute" of the candidate. For more detailed analysis and 13 additional key insights about Abivax, visit InvestingPro. In other recent news, Abivax SA has announced that it will present results from its Phase 3 induction trials for obefazimod, a treatment for ulcerative colitis, at the United European Gastroenterology Congress in Berlin. This presentation will highlight the efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis. Additionally, JMP Securities has raised its price target for Abivax to $114 from $95, maintaining a Market Outperform rating. The firm anticipates further analyses of obefazimod, particularly its efficacy in various patient subsets, including those who have failed other advanced treatments. Guggenheim has also reiterated a Buy rating on Abivax with a $101 price target, noting the promise shown by the company’s IBD drug data. This comes amid the release of abstracts from competing IBD treatments by Eli Lilly and Johnson & Johnson, which were discussed at the United European Gastroenterology Week. These developments suggest continued interest and confidence in Abivax’s potential advancements in ulcerative colitis treatment. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in LLY right now? With LLY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed LLY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including LLY, could offer substantial returns as the market corrects. In 2025 alone, our AI identified several undervalued stocks that later surged by 50% or more. Is LLY poised for similar growth? Don't miss the opportunity to find out. Abivax (NASDAQ:ABVX) is experiencing strong positive sentiment from the analyst community following the release of detailed safety data from its Phase 3 ABTECT trials for obefazimod, a treatment for ulcerative colitis. The data, presented at the United European Gastroenterology meeting, confirmed a "compelling and differentiated safety/tolerability profile" that was consistent with top-line results from July. This has prompted multiple analysts to reaffirm their bullish theses: Citizens reiterated its Market Outperform rating with a $114 price target, JMP Securities raised its target to $114 from $95, and Guggenheim maintained a Buy rating. The market has already priced in significant optimism, with the stock having returned 758% over the past year to trade at $83.92, near its 52-week high. The next critical catalyst is the forthcoming data on obefazimod's efficacy in treatment-resistant patients, which is seen as a key potential differentiator in a competitive field that includes major players like Eli Lilly and Johnson & Johnson.

Key Decisions for Investors

• Given the stock's 758% year-over-year gain, investors with existing positions should treat the upcoming efficacy data in treatment-resistant patients as a significant binary event that could either validate the current high valuation or trigger a substantial correction.
• Prospective investors should be cautious of initiating new positions near the 52-week high, as the strong safety profile appears to be largely priced in; awaiting the results on treatment-resistant patients may provide a more favorable risk-reward entry point.
• Monitor obefazimod's performance relative to competing IBD treatments from Eli Lilly and Johnson & Johnson, as its ability to demonstrate superior efficacy, particularly in hard-to-treat patient subsets, is crucial to justifying analyst price targets reaching up to $114.